November 25, 2025 — Leads & Copy — Vyome Holdings, Inc. has appointed Dr. Aditya Bardia as Senior Medical Advisor to guide the clinical development of VT-1953, its lead asset, for treating symptoms of malignant fungating wounds (MFW). The company is targeting approval for the treatment in 2026.
Dr. Bardia, who has experience leading clinical trials that have resulted in multiple drug approvals, will guide the clinical development of VT-1953, which is designed to treat the symptoms of MFW.
MFW is a debilitating condition that occurs in 5-14% of advanced cancer patients. It is estimated that there are over 650,000 patients with advanced cancer in the U.S., and approximately 10 million patients globally.
Dr. Bardia said he is excited to work with Vyome and guide the clinical development of VT-1953 for treating symptoms of MFW, a condition that can significantly impair quality of life for cancer patients.
Dr. Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School and Co-Founder of Vyome, said Dr. Bardia’s expertise in leading the development of multiple drugs aligns with the company’s strategy of designing robust, but cost-efficient, trials.
Venkat Nelabhotla, CEO of Vyome, said the collaboration with Dr. Bardia marks an important milestone in Vyome’s growth journey, adding that the company has a team in place to unlock the next milestones of value in its lead program.
According to the release, VT-1953 topical gel is designed to treat the symptoms of MFW by targeting the cause of malodor and inhibiting the drivers of inflammation. Prior clinical studies show the topical gel has been well tolerated in over 500 patients.
In an interim analysis, VT-1953 significantly reduced malodor symptoms (P<0.001), as scored by clinical investigators using a TELER Odor scale. Patients also reported a significant reduction in lesion pain scored on a visual analog scale (VAS) (P<0.001) and an improvement in quality of life (P<0.001). No clinically significant adverse trends were noted with VT-1953 administration.
References:
(1) Daniela Nigrelli, Francesca Gambalunga, Giuliano Anastasi, Angela Peghetti, Stefano Durante, Martina Giusti, Valentina Biagioli, Silvio Quirini, Laura Iacorossi, Roberto Latina. Malignant fungating wounds assessment in palliative care: a scoping review
https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1602493/full
(2) Alexander, S.J. An intense and unforgettable experience: the lived experience of malignant wounds from the perspectives of patients, caregivers and nurses. International Journal of Woundcare. 2010, 7:456-465
https://aacrjournals.org/cancerres/article/85/8_Supplement_2/CT091/761756/Abstract-CT091-Interim-results-from-a-phase-2
(3) Arshit Narang, Prashant Prakash Lad, Shiladitya Sengupta. Interim results from a phase 2 trial testing the safety and efficacy of VT-1953 topical gel in patients with malodorous malignant fungating wounds [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT091.
Contact: Vyome Holdings, Inc.
Source: Vyome Holdings, Inc.
